Financial statements Nexon Pharma
Balance sheet data of NEXON PHARMA
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
|---|---|---|---|---|---|---|---|
| Total assets | 95 219,85 | 269 762,73 | 484 600,42 | 170 644,15 | 484 374,46 | 509 488,85 | 704 425,52 |
| A. Fixed assets | 28 111,60 | 1 200,00 | 1 200,00 | 10 483,51 | 8 210,00 | 8 899,72 | 5 548,67 |
| B. Current assets | 67 108,25 | 268 562,73 | 483 400,42 | 160 160,64 | 476 164,46 | 500 589,13 | 698 876,85 |
| C. Share capital contributions (basic funds) | 0,00 | - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 95 219,85 | 269 762,73 | 484 600,42 | 170 644,15 | 484 374,46 | 509 488,85 | 704 425,52 |
| A. Equity | -62 847,81 | -68 380,41 | 94 286,81 | 149 135,49 | 437 276,75 | 498 314,51 | 660 310,59 |
| B. Liabilities and provisions for liabilities | 158 067,66 | 338 143,14 | 390 313,61 | 21 508,66 | 47 097,71 | 11 174,34 | 44 114,93 |
| I. Long-term liabilities | - | - | - | - | - | - | - |
| II. Short-term liabilities | - | - | - | - | - | - | - |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.
AD
AD